Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?

Publisher： Karger

E-ISSN： 1423-0399|96|1|20-24

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.96, Iss.1, 2016-0, pp. : 20-24

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of wireless web services to improve patient compliance in clinical drug trials

By Long Ju   Yuan Michael J.   Whinston Andrew B.   Yuan Chun-Su  

International Journal of Healthcare Technology and Management, Vol. 5, Iss. 6, 2004-05 ,pp. : 394-406

Inderscience Publishers

Access to resources Recommend Favorite

Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 675-678

John Wiley & Sons Inc

Access to resources Recommend Favorite

Non-compliance and therapeutic inertia: two unanswered questions in clinical practice

By Pallarés-Carratalá V.   Pascual Pérez R.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 839-840

Informa Healthcare

Access to resources Recommend Favorite

Bone marrow infection with bacillus Calmette-Guérin (BCG) after intravesical immunotherapy

By Nemeth Johannes  

Wiener klinische Wochenschrift, Vol. 120, Iss. 3-4, 2008-02 ,pp. : 121-123

Springer Publishing Company

Access to resources Recommend Favorite

Pure Squamous Cell Carcinoma after Intravesical BCG Treatment

By  

Urologia Internationalis, Vol. 74, Iss. 3, 2005-04 ,pp. : 283-285

Karger

Access to resources Recommend Favorite